Community Practice Connections™: Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Release Date: December 23, 2025

Expiration Date: December 23, 2026

Activity Overview

This Community Practice Connections™ program provides an in-depth review of foundational data supporting the optimal management of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancers (MBC) harboring ESR1 mutations. This unique, engaging, multimedia activity is ideal for the community-based clinician; it focuses on the practical aspects of treating patients with ESR1-mutated MBC, putting recent practice guidelines and trial data into clinical context with commentary by experts in the field. Participants will examine best practices for testing and identifying ESR1 mutations and discuss data supporting the use of oral selective estrogen receptor downregulators for treating these cancers. The program will also address the management of patients with concurrent PIK3CA/AKT/PTEN alterations and novel combination regimens being explored, providing practical insights to improve patient care.

Target Audience

This educational program is primarily directed toward community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of MBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2– MBC across the disease continuum
• Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2–MBC
• Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2– MBC
• Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2- MBC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.